Skip to content

Laparoscopic Appendectomy by Multi-port vs Single Port.

Randomized Controlled Trial Comparing Single Incision Laparoscopic Appendectomy Versus Standard Three Port Appendectomy in a Selected Cohort of Patients

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01720082
Acronym
AMUSING
Enrollment
300
Registered
2012-11-02
Start date
2013-03-31
Completion date
2014-02-28
Last updated
2012-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Appendicitis

Brief summary

Laparoscopic appendectomy (LA) is nowadays considered the gold standard in fertile women affected by uncomplicated appendicitis. The level of evidence for benefits from LA in this subgroup is high. Since the dissemination of single access surgery (no-scars surgery) ameliorated outcome has been supposed in these patients regarding post-operative pain, hospital stay and cosmetics results, and keeping the same safety as LA. This randomized controlled study is supposed to give answers to these questions.

Interventions

A multiport device will be introducted through a 2-2.5 transumbilical incision. Retraction of the appendix would be performed with a forceps. The mesoappendix will be divided with bipolar or monopolar cautery. The appendix stump will be ligated with suture loop or with an endo-stapler. The specimen will be delivered within a plastic bag or in any protected way (without any contact with the abdominal wall) via the umbilical port. Any fluid will be suctioned and washing performed if required. Fascial defects will be closed with 2-O polydioxanone sutures and skin closed with 4-O non-absorbable sutures. No pelvic drain will be inserted. A three-band dressing will be applied in the end.

PROCEDUREMultiport laparoscopic appendectomy

Three ports will be inserted as follows: One 10/12 umbilical port, one 5mm suprapubic (or right suprapubic)port, one 5mm or 10/12mm port in left iliac fossa (or left suprapubic). One additional trocar can be inserted following surgeons preference. Retraction of the appendix would be performed with a forceps. The mesoappendix will be divided with bipolar or monopolar cautery. The appendix stump will be ligated with suture loop or with an endo-stapler. The specimen will be delivered within a plastic bag or in any protected way (without any contact with the abdominal wall) via the umbilical port. Any fluid will be suctioned and washing performed if required. Fascial defects (10/12 trocars)will be closed with 2-O polydioxanone sutures and skin closed with 4-O non-absorbable sutures. No pelvic drain will be inserted. A three-band dressing will be applied in the end.

Sponsors

Società Italiana di Chirurgia Endoscopica e nuove tecnologie (SICE)
CollaboratorUNKNOWN
Associazione Chirurghi Ospedalieri Italiani
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
14 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* age: 14-60 * American Society of Anesthesiologists (ASA) score: I-III * absence of non-correctable coagulopathy (international normalized ratio \>1,5, or platelet count \<90 × 109/l). * diagnosis: acute appendicitis with surgical indication

Exclusion criteria

* Complicated appendicitis after exploration or previously diagnosed (CT) * Psychical inability * Pregnancy

Design outcomes

Primary

MeasureTime frame
Morbidity and mortality30 days

Secondary

MeasureTime frameDescription
Operative time1 day
Cosmetic result6 monthsVAS scale
Post-operative pain score3 daysVisual Analogic Scale (VAS scale)
Incision related morbidity6 monthsduring hospital stay (7days): infectious morbidity during follow-up (6 months): incisional hernias
Quality of life6 monthsGastro Intestinal Quality of Life Index (GIQLI) score at discharge and at 6 months follow-up
Post-operative hospital stay7 days

Countries

Italy

Contacts

Primary ContactNereo Vettoretto, MD
nereovet@gmail.com00393492237383

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026